SCHEMBL436967

SCHEMBL436967

CC(=O)Nc1c(C)cccc1C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.59
HPGD P15428 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.57
MEN1 O00255 3/20 0.55
CYP1A2 P05177 3/20 0.55
KMT2A Q03164 3/20 0.55
CYP2C9 P11712 2/20 0.55
NFKB1 P19838 1/20 0.55
CYP2C19 P33261 1/20 0.55
POLB P06746 3/20 0.53
MAPT P10636 4/20 0.52
LMNA P02545 4/20 0.52
SCN3A Q9NY46 3/20 0.52
ALOX15 P16050 2/20 0.52
SCN1A P35498 2/20 0.52
SCN2A Q99250 2/20 0.52
HDAC3 O15379 1/20 0.52
HDAC4 P56524 1/20 0.52
HDAC1 Q13547 1/20 0.52
HDAC7 Q8WUI4 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9168588 0.98 ALDH1A1 (0.57) ALDH1A1HPGDL3MBTL1MEN1CYP1A2
Piperazine SCHEMBL11871903 0.88 ALDH1A1 (0.48) ALDH1A1HPGDL3MBTL1MEN1CYP1A2
Diethylamine SCHEMBL17477112 0.88 MAPT (0.51) ALDH1A1HPGDL3MBTL1MEN1CYP1A2
SCHEMBL3810441 0.87 ALDH1A1 (0.52) ALDH1A1HPGDL3MBTL1MEN1CYP1A2
SCHEMBL11424223 0.87 ALDH1A1 (0.68) ALDH1A1HPGDL3MBTL1MEN1CYP1A2
SCHEMBL11780327 0.87 POLB (0.65) ALDH1A1HPGDL3MBTL1MEN1CYP1A2
SCHEMBL21480120 0.86 ALDH1A1 (0.50) ALDH1A1HPGDL3MBTL1MEN1CYP1A2
SCHEMBL2921682 0.86 PDK1 (0.58) ALDH1A1HPGDL3MBTL1GAA
SCHEMBL9187652 0.86 ALDH1A1 (0.50) ALDH1A1HPGDL3MBTL1MEN1CYP1A2
SCHEMBL3598057 0.86 ALDH1A1 (0.50) ALDH1A1HPGDL3MBTL1MEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025235864-A1 COATED NEEDLE ADMINISTRATION SYSTEMS EVOLUS, INC. (US) 2025-11-13 WO claimed
CN-112557569-B Method for detecting related substances in lidocaine 南京海纳医药科技股份有限公司 2023-04-11 CN claimed
CN-114524749-A N-diethyl acetyl-2, 6-dimethylaniline crystal and preparation method thereof 遂成药业股份有限公司 2022-05-24 CN claimed
US-20220096452-A1 LOCAL ANESTHETIC FOR THE TREATMENT OF NEUROLOGICAL SYMPTOMS RESULTING FROM BRAIN DYSFUNCTIONS ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) (FR) 2022-03-31 US claimed
CN-112557569-A Method for detecting related substances in lidocaine 南京海纳医药科技股份有限公司 2021-03-26 CN claimed
EP-3679010-A1 CARBONIC ACID ADDUCTS Jencluster GmbH (DE) 2020-07-15 EP claimed
CN-110461159-A Fungicidal compositions SYNGENTA PARTICIPATIONS AG 2019-11-15 CN claimed
EP-2674956-B1 HIGH THERMAL STABILITY PELLET COMPOSITIONS FOR THERMAL CUTOFF DEVICES AND METHODS FOR MAKING AND USE THEREOF THERM-O-DISC INCORPORATED (US) 2018-02-21 EP claimed
US-9765020-B2 Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis CELLIX BIO PRIVATE LIMITED (IN) 2017-09-19 US claimed
CN-105315170-B Dimethyl benzene ammonium long-chain compound, preparation, self-assembly structure and application 四川大学华西医院 2017-08-25 CN claimed
US-20100137299-A1 SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2010-06-03 US claimed
WO-2010045251-A2 SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS, INC. (CA) 2010-04-22 WO claimed
US-20090246605-A1 compressed compression spring positioned within a thermal cut-off composition to reduce the void volume inside a bare cell during initial overcharge; protective device for preventing the battery from exploding upon overcharge; improved thermal stability SAMSUNG SDI CO., LTD. (KR) 2009-10-01 US claimed
EP-1339701-B1 HETEROARYL ALKYL PIPERAZINE DERIVATIVES AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS INC (US) 2007-02-14 EP claimed
US-20060275666-A1 an electrode assembly whose top and bottom ends are blocked by a heat sensitive composition to reduce the void volume inside a bare cell during initial overcharge; preventing exploding and ignition; batteries have improved heat resistance SANSUMG SDI CO., LTD (KR) 2006-12-07 US claimed
US-6673257-B1 BLENDS EMPLOYING AT LEAST TWO ORGANIC COMPOUNDS HAVING KNOWN MELT TEMPERATURES, EXHIBIT IMPROVED THERMAL PROPERTIES AND PERFORMANCE CHARACTERISTICS THERM-O-DISC, INCORPORATED 2004-01-06 US claimed
EP-1326613-A1 USE OF SUBSTITUTED IMIDAZO 1,2-A]PYRIDINE-, IMIDAZO 1,2-A]PYRIMIDINE AND IMIDAZO 1,2-A]PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS Grünenthal GmbH (DE) 2003-07-16 EP claimed
WO-2002030428-A1 USE OF SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE-, IMIDAZO[1,2-A]PYRIMIDINE AND IMIDAZO[1,2-A]PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS Grünenthal GmbH (DE) 2002-04-18 WO claimed
US-4801706-A ANTIARRHYTHMIA HYPOTENSIVE AMERICAN HOME PRODUCTS CORPORATION (US) 1989-01-31 US claimed
US-4614798-A IMPROVED YIELD OF INTERMEDIATE USING TETRAHYDROFURAN OR A MIXTURE OF TOLUENE AND N,N-DIMETHYLACETAMIDE AS SOLVENT VETAMIX (US) 1986-09-30 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220096452-A1 LOCAL ANESTHETIC FOR THE TREATMENT OF NEUROLOGICAL SYMPTOMS RESULTING FROM BRAIN DYSFUNCTIONS FABP7, ALB, SLC1A2 ALDH1A1 1989/4885HPGD 4578/4885L3MBTL1 586/4885
US-20100137299-A1 SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS TRPV3, TRPV1, TRPC3 ALDH1A1 1020/4885HPGD 1101/4885L3MBTL1 2721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.